Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo

Autor: Jing-Jing Liu, Li-Jiao Wang, Shengyong Yang, Chun-Hui Zhang, Yong Xu, Yang Lingling, Jiao Yang, Pan Ji, Shan Feng, Zhi-Xing Cao, Ze-Rong Wang, Lei Zhong, Xiaoyan Wang, Yuquan Wei, Ren-Lin Zheng, Heng-Xiu Yan, Shuang Ma, Wei-Wei Li, Qi-Zheng Sun
Rok vydání: 2012
Předmět:
Zdroj: Journal of medicinal chemistry. 55(8)
ISSN: 1520-4804
Popis: Structure-activity relationship (SAR) studies of 2-(quinazolin-4-ylthio)thiazole derivatives, which are for optimizing the in vitro and in vivo antiacute myeloid leukemia (AML) activity of a previously identified FLT3 inhibitor 2-(6,7-dimethoxyquinazolin-4-ylthio)thiazole (1), are described. SAR studies centering around the head (thiazole) and tails (6- and 7-positions) of the quinazoline moiety of 1 led to the discovery of a series of compounds that exhibited significantly increased potency against FLT3-driven AML MV4-11 cells. Preliminary in vivo assays were carried out on three highly active compounds, whose results showed that 1-{5-[7-(3-morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea (20c) had the highest in vivo activity. Further in vitro and in vivo anti-AML studies were then performed on 20c; in an MV4-11 xenograft mouse model, a once-daily dose of 20c at 100 mg/kg for 18 days led to complete tumor regression without obvious toxicity. Western blot and immunohistochemical analysis were carried out to illustrate the mechanism of action of 20c.
Databáze: OpenAIRE